Award Number: W81XWH-06-2-0030

TITLE:
Original Protocol Title: Evaluation of a Non-Invasive Laser-Based Near-Infrared Spectrometric Glucose Monitor in Patients with Diabetes Mellitus

New Protocol Title: Evaluation of a Non-Invasive Alternative Glucose Monitor System in Patients with Diabetes Mellitus

PRINCIPAL INVESTIGATOR: Robert Vigersky, COL MC
Medical Director, Diabetes Institute, WRHCS

CONTRACTING ORGANIZATION:
T.R.U.E Research foundation
8610 New Braunfels
Suite 705
San Antonio, TX 78217

REPORT DATE: 1 July 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command,
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

X Approved for public release; distribution unlimited

☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
New Protocol Title: Evaluation of a Non-Invasive Alternative Glucose Monitor System in Patients with Diabetes Mellitus
14. ABSTRACT
The primary objectives of the study were to determine if the Nostix non-invasive glucometer monitored blood glucose levels in patients with insulin-requiring diabetes mellitus with accuracy comparable to that of standard invasive glucometers and using the Clark Error Grid determine whether or not errors in treatment would have occurred if the non-invasive device would have been used in place of the standard device. Eleven subjects (45 approved) were enrolled in the study before subject accrual was suspended due to the poor correlation between the Nostix non-invasive measurement and fingerstick measurements. The developers of Nostix are currently modifying the device in order to develop a more accurate method of non-invasively monitoring glucose levels. An amendment to test another non-invasive continuous glucose sensing device developed by Flexible Medical Systems was approved by the Department of Clinical Investigation at WRAMC in January 2008. FY08 AAMTI funding will support the efforts of a full-time project officer and the supplies required to complete the study.

15. SUBJECT TERMS
FlexMedPatch™, Transdermal Continuous Interstitial Glucose Monitoring System

16. SECURITY CLASSIFICATION OF:

<table>
<thead>
<tr>
<th>a. REPORT:</th>
<th>b. ABSTRACT:</th>
<th>c. THIS PAGE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

17. LIMITATION
UU

18. NUMBER

19a. NAME OF RESPONSIBLE PERSON

19b. TELEPHONE NUMBER (include area code)

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>5</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>7</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>7</td>
</tr>
<tr>
<td>Conclusion</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>8</td>
</tr>
<tr>
<td>Appendices</td>
<td>8</td>
</tr>
<tr>
<td>Supporting Data</td>
<td>8</td>
</tr>
</tbody>
</table>
INTRODUCTION

Diabetes Mellitus is a chronic disease whose complications of blindness, amputations, kidney failure, and cardiovascular disease are devastating in both their human and financial costs. Although it has been clearly demonstrated that complications can be prevented by improving blood glucose (BG) levels, achieving the levels of glycemic control necessary has proved to be an elusive target. The development of portable glucose meters has empowered patients to perform home blood glucose monitoring (HBGM), however, getting patients to do so has been difficult because each test requires a sometimes painful finger-stick (FS) to obtain blood for the test and the cost per test (about 50 cents) is limiting. Thus, the technology to monitor BG non-invasively and inexpensively has been the “Holy Grail” of diabetes management.

Numerous investigators have used a variety of technologies in an attempt to produce a non-invasive monitor. Because of both technical and performance limitations, however, only one device (GlucoWatch G2) has been approved and this has been shown to be inaccurate at clinically important low glucose levels. The primary objectives of this study are: 1) Determine the accuracy of non-invasive glucometer monitored blood glucose levels as compared to that of standard invasive glucometers; 2) Using the Clark Error Grid, determine whether or not errors in treatment would have occurred if the non-invasive device would have been used in place of the standard device.

BODY

This study involved the use of an experimental, non-invasive glucose monitoring device called Nostix. The Nostix device is a semiconductor laser-based near-infrared spectrophotometer (NIRS) developed to perform real-time photometric blood glucose measurements. It uses a probe, about 3 cm in length clipped on a finger. The device is low power and will expose subjects to low energy levels similar to that of a pulse oximeter. It is connected by cable to a computer and is designed to continuously and non-invasively monitor blood glucose concentrations. Our goal was to assess the accuracy and precision of this investigational device for detecting blood glucose concentration when compared to capillary finger-stick blood samples analyzed by a standard glucometer, the Hemocue® glucose meter, a laboratory-quality bedside glucose analyzer.

There were two primary objectives of this study: 1) determine if a non-invasive glucometer monitored blood glucose levels in patients with insulin-requiring diabetes mellitus with accuracy comparable to that of standard invasive glucometers. In order to achieve this objective, the investigators planned to compare the accuracy of this non-invasive device to a standard glucometer, the Hemocue® glucose meter, a laboratory-quality bedside glucose analyzer, in up to 45 subjects. The second objective was to use the Clark Error Grid to determine whether or not errors in treatment (i.e. the wrong dose of insulin) would have occurred if treatment decisions were based on the non-invasive test results rather than fingerstick results using a standard glucometer.

The initial results did not demonstrate the expected accuracy of the Nostix device, consequently the device is currently being redesigned by the manufacturer. Possible explanations of why the device failed to meet its goals include:

- Motion artifact of the probe which extended beyond the fingertip and thus, did not secure the emitter and detector from lateral motion.
  1. This may have caused a different tissue sample volume for each NIRS reading.
  2. Since the glucose absorbance is very small compared to that of water and hemoglobin different sample volumes may have slightly different water and hemoglobin levels that obscured the glucose absorbance.
- Systole of the cardiac cycle is used as a trigger to begin sampling because the optical absorbance by glucose is most consistent over time during systole.
  1. Some subjects had a weak pulse because of compromised circulation caused by diabetes.
  2. Some subjects began with an acceptable pulse amplitude, but experienced a decline in this level over the course of the study due to peripheral cooling or inactivity. (To minimize the affect of motion artifact, we asked the subjects to not move their hand).
Based on the findings of 11 subjects who were enrolled in the study, the device manufacturers are attempting to develop a reliable method of non-invasive glucose monitoring that would include the following refinements:

1. **Eliminate motion artifact.** Nostix is currently developing more stable probe designs which will reduce motion-related interference. Alternative sampling sites are also being assessed.

2. **Improve signal output.** Nostix has experimented with different methods to accomplish this and all possible solutions require more proprietary NIR emitters. Nostix is pursuing a vendor for such devices and has received estimated delivery times of 6-9 months since such an order would entail the production of custom semiconductor devices.

3. **Improve the analytical algorithm.** Use a multi-point calibration collected over 8 hours to then determine which of 132 possible weightings is most accurate in a particular patient and then apply that algorithm to future measurements.

This protocol was modified to test a new device, the FlexMedPatch™, and received approval from the Department of Clinical Investigation at WRAMC in January, 2008. The FlexMedPatch™ is a non-invasive, continuous glucose monitoring device that can be worn like a regular bandage, where it will measure glucose levels in the interstitial fluid (ISF) and transmit these measurements wirelessly to the patient’s cell phone, PDA, computer, or to a dedicated readout device. The system is small enough to allow discreet glucose monitoring, and the sampling and detection methods are painless, reliable, and continuous. It has been previously tested in animals. During 2003 and 2004, studies involving 32 animals were conducted at the Walter Reed Army Institute of Research (WRAIR). In the experiments, the animals glucose levels were monitored concomitantly with the FlexMedPatch™ transdermal microsystem, the Medtronic Continuous Glucose Monitoring System (CGMS) that continuously measures interstitial glucose levels via a subcutaneously inserted sensor, and by arterial blood draws using a YSI-2700 blood analyzer. Averaging over the 32 animal experiments, a 98% correlation was recorded between the FlexMedPatch™ output and 325 analyses from approximately ten arterial blood draws during each animal procedure. In these particular experiments, the glucose concentrations ranged from as low as 36 mg/dL to as high in one case as 540 mg/dL. FlexMedPatch™ measurements tracked the arterial values and were accurate to 5%. Preliminary patch designs have been used on the inventors during development. No data has been reported from these informal tests, but the sampling sensor worked as expected.

**Sampling method.** The biosensors contain an array of cells that sample from the ISF and measure glucose concentrations. The current prototypes contain 16 cells, but future prototypes can contain upwards of 1000 cells. Each individual cell performs both functions – sampling and measuring. The sensor is noninvasive and uses imperceptible levels of electricity and heat to temporarily open channels **between** cells in the stratum corneum. The device does not ablate or destroy any cells in the body. These channels are small enough that ISF flows reliably toward FlexMedPatch™ through capillary action. No vacuum is applied in the method, and none of the cells of the stratum corneum are damaged. Once the ISF contacts with the sensor, each cell contains a special coating that measures glucose concentration by a highly specific enzymatic electrochemical reaction.

Because the sensor utilizes microelectronics technology, each sampling cell acts on such a small area (approximately 50 micrometers) that the effects are imperceptible to humans. Indeed in preliminary, non-controlled tests during initial development, the inventors felt no sensation as the sensors sampled ISF. The enzymatic measurement reaction has been used before for reliable glucose detection.

The new device, FlexMedPatch™, has not been approved by the Food and Drug Administration for commercial use. The device is low power and will expose subjects to imperceptible levels of electricity and heat to temporarily open channels between cells in the stratum corneum. The original protocol was approved to enroll up to 45 subjects. We will enroll up to 32 subjects to use this device.
KEY RESEARCH ACCOMPLISHMENTS

• Eleven patients were enrolled in the original study before subject accrual was suspended pending technical modifications of the device.
• Despite several computer software upgrades in attempts to provide more accurate data analysis, the findings demonstrated that the correlation between the Nostix non-invasive measurements and fingerstick blood glucose measurements was poor when a prospective rather than retrospective algorithm was applied.
• The developers are continuing to refine the device and the analytical algorithms in an attempt to more accurately monitor glucose levels non-invasively.
• This protocol was modified to test a new non-invasive, continuous glucose sensing device, the FlexMedPatch™, and received approval from the Department of Clinical Investigation at WRAMC in January, 2008.

REPORTABLE OUTCOMES

• CPT Abel Alfonso MC presented an abstract of the device and study at the Annual Meeting of the Endocrine Society in San Francisco in June 2006
• There have been no other manuscripts or abstracts, patents or licenses applied for or issued, or degrees obtained that are supported by this award.
• There has been no development of cell lines, tissues or serum repositories or informatics.
• No additional funding has been requested for the development or use of this device.
• Funding for this study supported a full-time project officer for the period of time identified in this report and purchase of equipment necessary to the study.
• Nostix LLP has continued to attempt to refine their technology in order to provide a non-invasive method of accurately measuring glucose levels as well as other indicators of one’s metabolic status.
• Additional funding through FY08 AAMTI grant has been obtained and will support a full-time project officer and the purchase of equipment and supplies necessary to the study.

CONCLUSIONS

It is highly desirable to have a simple and cost-effective way for patients to self-monitor blood glucose levels without using invasive devices such as lancets in combination with commercially available glucose meters. A non-invasive glucometer would provide subjects and health care providers with the same information obtained with standard devices, but without the pain, blood loss and potential for infection associated with invasive glucose meters. The ability to self-monitor blood glucose readings without the need for invasive devices could not only reduce the morbidity associated with commercially available glucometers, but it could potentially provide a significant cost-saving to the military medical system.

The ability to non-invasively monitor one’s metabolic status without the need for an invasive device has particular relevance to the military community, both the warfighter and patients. While we plan only to use this device to measure glucose, the FlexMedPatch™ also has the capability of measuring tissue hydration, oxygen, hematocrit, albumin and other important parameters of health. Thus, when enabled with wireless technology and an alarm, this device would permit the warfighter’s hydration and metabolic status to be monitored both on site and at a distance thus alerting the soldier and his/her commander of critical health status changes. For beneficiaries of military health care who have diabetes, a non-invasive method of measuring glucose levels allows patients to check glucose levels at any time without stopping to prepare and use the equipment (glucometer, strips, lancets, & lancing device) required to obtain a FS specimen. The portability of the monitor and the ease with which BG levels can be obtained lends itself to more frequent monitoring as well as rapid recognition and treatment of high and low BG levels. Faster recognition and treatment of hyperglycemia (high BG) and hypoglycemia (low BG) will decrease the development of short and long term complications, thus enhancing the well-being and performance of the individual and decreasing medical expenses. If ultimately equipped with an alarm, it would prevent dangerous nocturnal hypoglycemia and resultant seizures or loss of
REFERENCES


APPENDICES

N/A

SUPPORTING DATA

N/A